MOUNTAIN VIEW, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) announced today that a newly-published study demonstrated Qsymia ® (phentermine and topiramate extended-release) capsules CIV produced significantly greater weight loss, and at lower doses, compared to phentermine or topiramate administered as monotherapies in obese adults. Among patients taking the once-daily extended-release formulation, Qsymia was generally well tolerated and improved blood pressure. In this study, the effect of Qsymia on heart rate was similar to placebo. The 28-week study was published online in the journal Obesity. Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes or high cholesterol. In the study, patients completing 28 weeks of treatment on Qsymia 7.5 mg/46 mg and 15 mg/92 mg were able to reduce their weight by 11% and 12%, respectively. Greater improvements in waist circumference, glycosylated haemoglobin (HbA1c) and adiponectin were also seen in Qsymia-treated patients compared to those receiving treatment with the individual components. "The extended-release formulation of Qsymia is key to providing the greatest level of weight-loss efficacy while minimizing tolerability concerns," said Louis Aronne, MD, Professor of Clinical Medicine at Weill Cornell Medical College and Medical Director of Center for Weight Management and Metabolic Clinical Research at New York-Presbyterian/Weill Cornell Medical Center, and a lead investigator in the study. "For decades, phentermine has been a mainstay in the medical treatment of obesity, but when combined with topiramate in an extended-release formulation, we see greater weight loss, less heart rate increase and greater reduction in blood pressure."